ZA200603617B - Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder - Google Patents
Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder Download PDFInfo
- Publication number
- ZA200603617B ZA200603617B ZA200603617A ZA200603617A ZA200603617B ZA 200603617 B ZA200603617 B ZA 200603617B ZA 200603617 A ZA200603617 A ZA 200603617A ZA 200603617 A ZA200603617 A ZA 200603617A ZA 200603617 B ZA200603617 B ZA 200603617B
- Authority
- ZA
- South Africa
- Prior art keywords
- benzofuran
- methyl
- benzenesulfonamide
- methoxy
- trifluoroacetate
- Prior art date
Links
- 238000011321 prophylaxis Methods 0.000 title claims description 7
- 238000011282 treatment Methods 0.000 title claims description 7
- 108091005435 5-HT6 receptors Proteins 0.000 title description 2
- 150000001907 coumarones Chemical class 0.000 title description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 58
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 36
- -1 3,3,3-trifluoropropyl Chemical group 0.000 claims description 32
- 125000001072 heteroaryl group Chemical group 0.000 claims description 29
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 24
- 208000035475 disorder Diseases 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 21
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 125000004432 carbon atom Chemical group C* 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 206010033664 Panic attack Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 208000019906 panic disease Diseases 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 235000019786 weight gain Nutrition 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000032841 Bulimia Diseases 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 206010013654 Drug abuse Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000026139 Memory disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 208000022531 anorexia Diseases 0.000 claims description 4
- 208000014679 binge eating disease Diseases 0.000 claims description 4
- 208000010877 cognitive disease Diseases 0.000 claims description 4
- 206010061428 decreased appetite Diseases 0.000 claims description 4
- 230000006735 deficit Effects 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 230000001771 impaired effect Effects 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 230000007514 neuronal growth Effects 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 33
- OWCDMRFUFMERMZ-UHFFFAOYSA-N benzenesulfonamide;hydrochloride Chemical compound Cl.NS(=O)(=O)C1=CC=CC=C1 OWCDMRFUFMERMZ-UHFFFAOYSA-N 0.000 claims 7
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 3
- KJQIPBGEBFRXEE-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[5-(piperidin-4-ylmethyl)-1-benzofuran-7-yl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(CC2CCNCC2)=CC2=C1OC=C2 KJQIPBGEBFRXEE-UHFFFAOYSA-N 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- ALDMJOLHPMQFMI-UHFFFAOYSA-N 1-[[5-(2-methoxy-5-methylphenyl)sulfonyl-1-benzofuran-7-yl]methyl]-1,4-diazepane Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)C1=CC(CN2CCNCCC2)=C(OC=C2)C2=C1 ALDMJOLHPMQFMI-UHFFFAOYSA-N 0.000 claims 1
- JAIZHDJQXZYFRT-UHFFFAOYSA-N 1-[[5-(2-methoxy-5-methylphenyl)sulfonyl-1-benzofuran-7-yl]methyl]-2-methylpiperazine Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)C1=CC(CN2C(CNCC2)C)=C(OC=C2)C2=C1 JAIZHDJQXZYFRT-UHFFFAOYSA-N 0.000 claims 1
- LLTPJSZRHGVWDR-UHFFFAOYSA-N 1-[[5-(2-methoxy-5-methylphenyl)sulfonyl-1-benzofuran-7-yl]methyl]-3-methylpiperazine Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)C1=CC(CN2CC(C)NCC2)=C(OC=C2)C2=C1 LLTPJSZRHGVWDR-UHFFFAOYSA-N 0.000 claims 1
- FMXNKOAGAOBOHX-UHFFFAOYSA-N 1-[[5-(2-methoxy-5-methylphenyl)sulfonyl-1-benzofuran-7-yl]methyl]piperazine Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)C1=CC(CN2CCNCC2)=C(OC=C2)C2=C1 FMXNKOAGAOBOHX-UHFFFAOYSA-N 0.000 claims 1
- XGDQQELZXXCBOM-UHFFFAOYSA-N 1-[[5-(4-methylphenyl)sulfonyl-1-benzofuran-7-yl]methyl]-1,4-diazepane Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1=CC(CN2CCNCCC2)=C(OC=C2)C2=C1 XGDQQELZXXCBOM-UHFFFAOYSA-N 0.000 claims 1
- WHDGGCORCWUPRS-UHFFFAOYSA-N 1-[[5-(4-methylphenyl)sulfonyl-1-benzofuran-7-yl]methyl]piperazine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1=CC(CN2CCNCC2)=C(OC=C2)C2=C1 WHDGGCORCWUPRS-UHFFFAOYSA-N 0.000 claims 1
- ZFYNFLJGQITZTL-UHFFFAOYSA-N 1-[[5-(benzenesulfonyl)-1-benzofuran-7-yl]methyl]-1,4-diazepane Chemical compound C=1C(CN2CCNCCC2)=C2OC=CC2=CC=1S(=O)(=O)C1=CC=CC=C1 ZFYNFLJGQITZTL-UHFFFAOYSA-N 0.000 claims 1
- KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 claims 1
- QICPUDQULPWFHE-UHFFFAOYSA-N 2-[4-[5-[(2-chlorophenyl)sulfonylamino]-1-benzofuran-7-yl]piperazin-1-yl]-n,n-diethylacetamide;hydrochloride Chemical compound Cl.C1CN(CC(=O)N(CC)CC)CCN1C1=CC(NS(=O)(=O)C=2C(=CC=CC=2)Cl)=CC2=C1OC=C2 QICPUDQULPWFHE-UHFFFAOYSA-N 0.000 claims 1
- WAEBZEYPUCZECP-UHFFFAOYSA-N 2-chloro-n-[7-(1,4-diazepan-1-ylmethyl)-1-benzofuran-5-yl]benzenesulfonamide;dihydrochloride Chemical compound Cl.Cl.ClC1=CC=CC=C1S(=O)(=O)NC1=CC(CN2CCNCCC2)=C(OC=C2)C2=C1 WAEBZEYPUCZECP-UHFFFAOYSA-N 0.000 claims 1
- HWZFCASMKUSCKV-UHFFFAOYSA-N 2-chloro-n-[7-(piperazin-1-ylmethyl)-1-benzofuran-5-yl]benzenesulfonamide;dihydrochloride Chemical compound Cl.Cl.ClC1=CC=CC=C1S(=O)(=O)NC1=CC(CN2CCNCC2)=C(OC=C2)C2=C1 HWZFCASMKUSCKV-UHFFFAOYSA-N 0.000 claims 1
- AZLQNLLWIZSWQR-UHFFFAOYSA-N 2-chloro-n-[7-(pyridin-4-ylamino)-1-benzofuran-5-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.ClC1=CC=CC=C1S(=O)(=O)NC1=CC(NC=2C=CN=CC=2)=C(OC=C2)C2=C1 AZLQNLLWIZSWQR-UHFFFAOYSA-N 0.000 claims 1
- QYGULQNEYLPTKZ-UHFFFAOYSA-N 2-chloro-n-[7-[(3-methylpiperazin-1-yl)methyl]-1-benzofuran-5-yl]benzenesulfonamide Chemical compound C1CNC(C)CN1CC1=CC(NS(=O)(=O)C=2C(=CC=CC=2)Cl)=CC2=C1OC=C2 QYGULQNEYLPTKZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- YIWKPGFDJBRUOM-UHFFFAOYSA-N 2-methoxy-5-methyl-n-(7-pyridin-4-yl-1-benzofuran-5-yl)benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(C=2C=CN=CC=2)=C(OC=C2)C2=C1 YIWKPGFDJBRUOM-UHFFFAOYSA-N 0.000 claims 1
- CKOOEKVOEDHLIL-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[5-[(3-methylpiperazin-1-yl)methyl]-1-benzofuran-7-yl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(CN2CC(C)NCC2)=CC2=C1OC=C2 CKOOEKVOEDHLIL-UHFFFAOYSA-N 0.000 claims 1
- KJRCYEGDNJXCFA-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[7-(piperazin-1-ylmethyl)-1-benzofuran-5-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(CN2CCNCC2)=C(OC=C2)C2=C1 KJRCYEGDNJXCFA-UHFFFAOYSA-N 0.000 claims 1
- IFJZURPIXQMRPP-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[7-(piperidin-4-ylmethyl)-1-benzofuran-5-yl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(CC2CCNCC2)=C(OC=C2)C2=C1 IFJZURPIXQMRPP-UHFFFAOYSA-N 0.000 claims 1
- BEHLQKRPFMUPOH-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[7-(pyridin-4-ylamino)-1-benzofuran-5-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(NC=2C=CN=CC=2)=C(OC=C2)C2=C1 BEHLQKRPFMUPOH-UHFFFAOYSA-N 0.000 claims 1
- NEJBVUVZZUELDR-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[7-[(2-methylpiperazin-1-yl)methyl]-1-benzofuran-5-yl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(CN2C(CNCC2)C)=C(OC=C2)C2=C1 NEJBVUVZZUELDR-UHFFFAOYSA-N 0.000 claims 1
- OBFUCTKBNTZKKN-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[7-[(3-methylpiperazin-1-yl)methyl]-1-benzofuran-5-yl]benzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(CN2CC(C)NCC2)=C(OC=C2)C2=C1 OBFUCTKBNTZKKN-UHFFFAOYSA-N 0.000 claims 1
- ZHJPDHCBVPUESK-UHFFFAOYSA-N 2-methoxy-5-methyl-n-[7-[4-(3,3,3-trifluoropropyl)piperazin-1-yl]-1-benzofuran-5-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(N2CCN(CCC(F)(F)F)CC2)=C(OC=C2)C2=C1 ZHJPDHCBVPUESK-UHFFFAOYSA-N 0.000 claims 1
- WSDUYWLJIQTFFC-UHFFFAOYSA-N 2-methyl-n-[7-(piperazin-1-ylmethyl)-1-benzofuran-5-yl]benzenesulfonamide Chemical compound CC1=CC=CC=C1S(=O)(=O)NC1=CC(CN2CCNCC2)=C(OC=C2)C2=C1 WSDUYWLJIQTFFC-UHFFFAOYSA-N 0.000 claims 1
- WKDBPLPSTOPPCZ-UHFFFAOYSA-N 2-methyl-n-[7-[(2-methylpiperazin-1-yl)methyl]-1-benzofuran-5-yl]benzenesulfonamide;dihydrochloride Chemical compound Cl.Cl.CC1CNCCN1CC1=CC(NS(=O)(=O)C=2C(=CC=CC=2)C)=CC2=C1OC=C2 WKDBPLPSTOPPCZ-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- PBDCCLOBHVUQGW-UHFFFAOYSA-N 3,4-dimethoxy-n-(7-morpholin-4-yl-1-benzofuran-5-yl)benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)NC1=CC(N2CCOCC2)=C(OC=C2)C2=C1 PBDCCLOBHVUQGW-UHFFFAOYSA-N 0.000 claims 1
- RQNARKFETTZPLJ-UHFFFAOYSA-N 3,4-dimethoxy-n-(7-pyrrolidin-1-yl-1-benzofuran-5-yl)benzenesulfonamide Chemical compound C1=C(OC)C(OC)=CC=C1S(=O)(=O)NC1=CC(N2CCCC2)=C(OC=C2)C2=C1 RQNARKFETTZPLJ-UHFFFAOYSA-N 0.000 claims 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims 1
- CAZWDPLLKUTHCH-UHFFFAOYSA-N 4-fluoro-n-(7-piperidin-1-yl-1-benzofuran-5-yl)benzenesulfonamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC1=CC(N2CCCCC2)=C(OC=C2)C2=C1 CAZWDPLLKUTHCH-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- YAQRGFQRKCSWJJ-UHFFFAOYSA-N 7-(1,4-diazepan-1-ylmethyl)-n-(2-methoxy-5-methylphenyl)-1-benzofuran-5-sulfonamide Chemical compound COC1=CC=C(C)C=C1NS(=O)(=O)C1=CC(CN2CCNCCC2)=C(OC=C2)C2=C1 YAQRGFQRKCSWJJ-UHFFFAOYSA-N 0.000 claims 1
- GEPAPZRTFUQLKH-UHFFFAOYSA-N 7-(1,4-diazepan-1-ylmethyl)-n-(2-methylphenyl)-1-benzofuran-5-sulfonamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC(CN2CCNCCC2)=C(OC=C2)C2=C1 GEPAPZRTFUQLKH-UHFFFAOYSA-N 0.000 claims 1
- JUEZJYYOKAAPGB-UHFFFAOYSA-N 7-[(3,5-dimethylpiperazin-1-yl)methyl]-n-(2-methylphenyl)-1-benzofuran-5-sulfonamide Chemical compound C1C(C)NC(C)CN1CC1=CC(S(=O)(=O)NC=2C(=CC=CC=2)C)=CC2=C1OC=C2 JUEZJYYOKAAPGB-UHFFFAOYSA-N 0.000 claims 1
- DJNOGCMHQCGXFT-CALCHBBNSA-N 7-[[(3r,5s)-3,5-dimethylpiperazin-1-yl]methyl]-n-(2-methoxy-5-methylphenyl)-1-benzofuran-5-sulfonamide Chemical compound COC1=CC=C(C)C=C1NS(=O)(=O)C1=CC(CN2C[C@@H](C)N[C@@H](C)C2)=C(OC=C2)C2=C1 DJNOGCMHQCGXFT-CALCHBBNSA-N 0.000 claims 1
- COXNIUDFLPLZQB-UHFFFAOYSA-N N-[7-(1,4-diazepan-1-ylmethyl)-1-benzofuran-5-yl]-2-methylbenzenesulfonamide dihydrochloride Chemical compound Cl.Cl.Cc1ccccc1S(=O)(=O)Nc1cc(CN2CCCNCC2)c2occc2c1 COXNIUDFLPLZQB-UHFFFAOYSA-N 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IQOUPFKVEHGBKB-UHFFFAOYSA-N n,n-diethyl-2-[4-[5-[(2-methoxy-5-methylphenyl)sulfonylamino]-1-benzofuran-7-yl]piperazin-1-yl]acetamide;hydrochloride Chemical compound Cl.C1CN(CC(=O)N(CC)CC)CCN1C1=CC(NS(=O)(=O)C=2C(=CC=C(C)C=2)OC)=CC2=C1OC=C2 IQOUPFKVEHGBKB-UHFFFAOYSA-N 0.000 claims 1
- PZNHLVRIWNOIRI-UHFFFAOYSA-N n-(2-methoxy-5-methylphenyl)-7-(piperazin-1-ylmethyl)-1-benzofuran-5-sulfonamide Chemical compound COC1=CC=C(C)C=C1NS(=O)(=O)C1=CC(CN2CCNCC2)=C(OC=C2)C2=C1 PZNHLVRIWNOIRI-UHFFFAOYSA-N 0.000 claims 1
- HYZZYTSIOUCFBU-UHFFFAOYSA-N n-(2-methoxy-5-methylphenyl)-7-[(2-methylpiperazin-1-yl)methyl]-1-benzofuran-5-sulfonamide Chemical compound COC1=CC=C(C)C=C1NS(=O)(=O)C1=CC(CN2C(CNCC2)C)=C(OC=C2)C2=C1 HYZZYTSIOUCFBU-UHFFFAOYSA-N 0.000 claims 1
- GMYWAVFQGNKVOI-UHFFFAOYSA-N n-(2-methoxy-5-methylphenyl)-7-[(3-methylpiperazin-1-yl)methyl]-1-benzofuran-5-sulfonamide;hydrochloride Chemical compound Cl.COC1=CC=C(C)C=C1NS(=O)(=O)C1=CC(CN2CC(C)NCC2)=C(OC=C2)C2=C1 GMYWAVFQGNKVOI-UHFFFAOYSA-N 0.000 claims 1
- GGNRMIDIDKUHFX-UHFFFAOYSA-N n-(2-methylphenyl)-7-(piperazin-1-ylmethyl)-1-benzofuran-5-sulfonamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC(CN2CCNCC2)=C(OC=C2)C2=C1 GGNRMIDIDKUHFX-UHFFFAOYSA-N 0.000 claims 1
- ZXTPLYKULXTZTO-UHFFFAOYSA-N n-(2-methylphenyl)-7-(piperidin-3-ylmethyl)-1-benzofuran-5-sulfonamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC(CC2CNCCC2)=C(OC=C2)C2=C1 ZXTPLYKULXTZTO-UHFFFAOYSA-N 0.000 claims 1
- DDVBJKGJVDDROE-UHFFFAOYSA-N n-(2-methylphenyl)-7-(piperidin-4-ylmethyl)-1-benzofuran-5-sulfonamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC(CC2CCNCC2)=C(OC=C2)C2=C1 DDVBJKGJVDDROE-UHFFFAOYSA-N 0.000 claims 1
- KSEXFQAEMWKZIO-UHFFFAOYSA-N n-(2-methylphenyl)-7-(pyrrolidin-3-ylmethyl)-1-benzofuran-5-sulfonamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC(CC2CNCC2)=C(OC=C2)C2=C1 KSEXFQAEMWKZIO-UHFFFAOYSA-N 0.000 claims 1
- AOYREIAVHCCTHQ-UHFFFAOYSA-N n-(2-methylphenyl)-7-[(3-methylpiperazin-1-yl)methyl]-1-benzofuran-5-sulfonamide Chemical compound C1CNC(C)CN1CC1=CC(S(=O)(=O)NC=2C(=CC=CC=2)C)=CC2=C1OC=C2 AOYREIAVHCCTHQ-UHFFFAOYSA-N 0.000 claims 1
- AKHZJDJPFXVSEU-QGZVFWFLSA-N n-(2-methylphenyl)-7-[[[(3r)-pyrrolidin-3-yl]amino]methyl]-1-benzofuran-5-sulfonamide Chemical compound CC1=CC=CC=C1NS(=O)(=O)C1=CC(CN[C@H]2CNCC2)=C(OC=C2)C2=C1 AKHZJDJPFXVSEU-QGZVFWFLSA-N 0.000 claims 1
- OVNLLKUEXOAQAZ-UHFFFAOYSA-N n-(7-piperidin-1-yl-1-benzofuran-5-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1C=COC1=1)=CC=1N1CCCCC1 OVNLLKUEXOAQAZ-UHFFFAOYSA-N 0.000 claims 1
- MAWJJHGKHAHHGI-UHFFFAOYSA-N n-(7-pyrrolidin-1-yl-1-benzofuran-5-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C=C1C=COC1=1)=CC=1N1CCCC1 MAWJJHGKHAHHGI-UHFFFAOYSA-N 0.000 claims 1
- XBAIJHRIPBXNSV-UHFFFAOYSA-N n-[7-(1,4-diazepan-1-ylmethyl)-1-benzofuran-5-yl]thiophene-2-sulfonamide;dihydrochloride Chemical compound Cl.Cl.C=1C=CSC=1S(=O)(=O)NC(C=C1C=COC1=1)=CC=1CN1CCCNCC1 XBAIJHRIPBXNSV-UHFFFAOYSA-N 0.000 claims 1
- GFKAKFFYNUARAC-UHFFFAOYSA-N n-[7-(2-aminopiperidin-1-yl)-1-benzofuran-5-yl]-2-(trifluoromethyl)benzenesulfonamide;hydrochloride Chemical compound Cl.NC1CCCCN1C1=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(F)(F)F)=CC2=C1OC=C2 GFKAKFFYNUARAC-UHFFFAOYSA-N 0.000 claims 1
- BSDUARSUTTUSEK-UHFFFAOYSA-N n-[7-(2-aminopiperidin-1-yl)-1-benzofuran-5-yl]-2-chlorobenzenesulfonamide;hydrochloride Chemical compound Cl.NC1CCCCN1C1=CC(NS(=O)(=O)C=2C(=CC=CC=2)Cl)=CC2=C1OC=C2 BSDUARSUTTUSEK-UHFFFAOYSA-N 0.000 claims 1
- MOEAPVXVEBXGCT-UHFFFAOYSA-N n-[7-(2-aminopiperidin-1-yl)-1-benzofuran-5-yl]-2-methoxy-5-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(N2C(CCCC2)N)=C(OC=C2)C2=C1 MOEAPVXVEBXGCT-UHFFFAOYSA-N 0.000 claims 1
- AZFDIVTXBMTBFH-UHFFFAOYSA-N n-[7-(2-aminopiperidin-1-yl)-1-benzofuran-5-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.NC1CCCCN1C1=CC(NS(=O)(=O)C=2C=CC=CC=2)=CC2=C1OC=C2 AZFDIVTXBMTBFH-UHFFFAOYSA-N 0.000 claims 1
- BUHFJWDIORBUJW-UHFFFAOYSA-N n-[7-(6-aminopyridin-3-yl)-1-benzofuran-5-yl]-2-methoxy-5-methylbenzenesulfonamide Chemical compound COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(C=2C=NC(N)=CC=2)=C(OC=C2)C2=C1 BUHFJWDIORBUJW-UHFFFAOYSA-N 0.000 claims 1
- UHLWCJCACOWNMF-UHFFFAOYSA-N n-[7-(piperazin-1-ylmethyl)-1-benzofuran-5-yl]thiophene-2-sulfonamide Chemical compound C=1C=CSC=1S(=O)(=O)NC(C=C1C=COC1=1)=CC=1CN1CCNCC1 UHLWCJCACOWNMF-UHFFFAOYSA-N 0.000 claims 1
- UBWRINBJLUBSJL-UHFFFAOYSA-N n-[7-(pyridin-4-ylamino)-1-benzofuran-5-yl]benzenesulfonamide;hydrochloride Chemical compound Cl.C=1C=CC=CC=1S(=O)(=O)NC(C=C1C=COC1=1)=CC=1NC1=CC=NC=C1 UBWRINBJLUBSJL-UHFFFAOYSA-N 0.000 claims 1
- IKLNHHVDOZYEEG-UHFFFAOYSA-N n-[7-[(3-methylpiperazin-1-yl)methyl]-1-benzofuran-5-yl]-2-(trifluoromethyl)benzenesulfonamide Chemical compound C1CNC(C)CN1CC1=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(F)(F)F)=CC2=C1OC=C2 IKLNHHVDOZYEEG-UHFFFAOYSA-N 0.000 claims 1
- OKKSKARZNVJRCC-PPPUBMIESA-N n-[7-[(3r,4s)-3-fluoropiperidin-4-yl]oxy-1-benzofuran-5-yl]-2-methoxy-5-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.COC1=CC=C(C)C=C1S(=O)(=O)NC1=CC(O[C@@H]2[C@@H](CNCC2)F)=C(OC=C2)C2=C1 OKKSKARZNVJRCC-PPPUBMIESA-N 0.000 claims 1
- OZKXUWSCVDMBSE-UNTBIKODSA-N n-[7-[[(2r)-1-ethylpyrrolidin-2-yl]methylamino]-1-benzofuran-5-yl]-2-(trifluoromethyl)benzenesulfonamide;hydrochloride Chemical compound Cl.CCN1CCC[C@@H]1CNC1=CC(NS(=O)(=O)C=2C(=CC=CC=2)C(F)(F)F)=CC2=C1OC=C2 OZKXUWSCVDMBSE-UNTBIKODSA-N 0.000 claims 1
- RQWJSSDKPWUKFR-FSRHSHDFSA-N n-[7-[[(2r)-1-ethylpyrrolidin-2-yl]methylamino]-1-benzofuran-5-yl]-2-methoxy-5-methylbenzenesulfonamide;hydrochloride Chemical compound Cl.CCN1CCC[C@@H]1CNC1=CC(NS(=O)(=O)C=2C(=CC=C(C)C=2)OC)=CC2=C1OC=C2 RQWJSSDKPWUKFR-FSRHSHDFSA-N 0.000 claims 1
- SWTNSLGGNFIBMQ-PKLMIRHRSA-N n-[7-[[(2r)-1-ethylpyrrolidin-2-yl]methylamino]-1-benzofuran-5-yl]thiophene-2-sulfonamide;hydrochloride Chemical compound Cl.CCN1CCC[C@@H]1CNC1=CC(NS(=O)(=O)C=2SC=CC=2)=CC2=C1OC=C2 SWTNSLGGNFIBMQ-PKLMIRHRSA-N 0.000 claims 1
- QZASZFWVVPSCQA-SJORKVTESA-N n-[7-[[(2s,5r)-2,5-dimethylpiperazin-1-yl]methyl]-1-benzofuran-5-yl]-2-methylbenzenesulfonamide Chemical compound C[C@H]1CN[C@H](C)CN1CC1=CC(NS(=O)(=O)C=2C(=CC=CC=2)C)=CC2=C1OC=C2 QZASZFWVVPSCQA-SJORKVTESA-N 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 17
- 229910052799 carbon Inorganic materials 0.000 description 16
- 125000004093 cyano group Chemical group *C#N 0.000 description 14
- 229910052731 fluorine Inorganic materials 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- 239000011737 fluorine Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- 238000004965 Hartree-Fock calculation Methods 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
- 125000003386 piperidinyl group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HHRFWSALGNYPHA-UHFFFAOYSA-N [N].C1CNCCN1 Chemical group [N].C1CNCCN1 HHRFWSALGNYPHA-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- KMCHWHGTFVQFOO-UHFFFAOYSA-N piperazine;thiomorpholine Chemical compound C1CNCCN1.C1CSCCN1 KMCHWHGTFVQFOO-UHFFFAOYSA-N 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0303480A SE0303480D0 (sv) | 2003-12-19 | 2003-12-19 | Benzofuranes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200603617B true ZA200603617B (en) | 2007-09-26 |
Family
ID=30768799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200603617A ZA200603617B (en) | 2003-12-19 | 2004-12-20 | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7820675B2 (sv) |
| JP (1) | JP4739230B2 (sv) |
| CN (1) | CN1886392A (sv) |
| SE (1) | SE0303480D0 (sv) |
| ZA (1) | ZA200603617B (sv) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7582767B2 (en) * | 2005-06-17 | 2009-09-01 | Biovitrum Ab (Publ.) | Substituted sulphonamide compound and uses thereof |
| WO2007079078A1 (en) | 2005-12-29 | 2007-07-12 | Bayer Schering Pharma Aktiengesellschaft | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| US20080031822A1 (en) * | 2006-04-13 | 2008-02-07 | Frank Porreca | Methods of modeling migraine pain and identifying candidate compounds for the treatment of migraine |
| US7842713B2 (en) * | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
| WO2008118364A1 (en) * | 2007-03-23 | 2008-10-02 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of modeling migraine pain and identifying candidate compounds for the treatment of migraine |
| EP2344458A1 (en) | 2008-09-11 | 2011-07-20 | Pfizer Inc. | Heteroaryls amide derivatives and their use as glucokinase activators |
| EA018894B1 (ru) * | 2009-03-11 | 2013-11-29 | Пфайзер Инк. | N,n-диметил-5-(2-метил-6-((5-метилпиразин-2-ил)карбамоил)бензо-фуран-4-илокси)пиримидин-2-карбоксамид, используемый в качестве активатора глюкокиназы, и содержащая его фармацев-тическая композиция |
| WO2012087833A1 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Hepatitis c inhibitors and uses thereof |
| RU2686101C2 (ru) | 2013-03-12 | 2019-04-24 | Селтакссис, Инк. | Способы ингибирования лейкотриен- а4-гидролазы |
| BR112015022226A2 (pt) | 2013-03-14 | 2017-07-18 | Celtaxsys Inc | inibidores de leucotrieno a4 hidrolase |
| CA2906086A1 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| WO2014152518A2 (en) | 2013-03-14 | 2014-09-25 | Celtaxsys, Inc. | Inhibitors of leukotriene a4 hydrolase |
| CN104529962B (zh) * | 2014-12-22 | 2016-08-17 | 中科院广州化学有限公司 | 一种2-烷氨基-3-氰基苯并呋喃类化合物及制备方法 |
| WO2019168874A1 (en) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| US10898484B2 (en) | 2018-05-31 | 2021-01-26 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ250916A (en) * | 1993-02-27 | 1995-08-28 | Nihon Nohyaku Co Ltd | N-heteroaryl-n'-phenylureas, their use as acat inhibitors |
| GB9408577D0 (en) * | 1994-04-29 | 1994-06-22 | Fujisawa Pharmaceutical Co | New compound |
| US5597826A (en) | 1994-09-14 | 1997-01-28 | Pfizer Inc. | Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist |
| US5939451A (en) | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
| CA2268164A1 (en) * | 1996-10-08 | 1998-04-16 | Yao-Chang Xu | New serotonin 5-ht1f agonists |
| DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
| WO1999002502A2 (en) | 1997-07-11 | 1999-01-21 | Smithkline Beecham Plc | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
| GB9801392D0 (en) | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
| GB9803411D0 (en) | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
| WO2000034242A1 (en) | 1998-12-11 | 2000-06-15 | Virginia Commonwealth University | Selective 5-ht6 receptor ligands |
| US6191141B1 (en) | 1999-08-12 | 2001-02-20 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
| GB9926302D0 (en) | 1999-11-05 | 2000-01-12 | Smithkline Beecham Plc | Novel compounds |
| CA2440238C (en) * | 2001-03-16 | 2011-09-13 | Abbott Laboratories | Novel amines as histamine-3 receptor ligands and their therapeutic applications |
| JP4187642B2 (ja) | 2001-06-07 | 2008-11-26 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６受容体親和性を有する新規インドール誘導体 |
| CA2445653A1 (en) * | 2001-06-11 | 2002-12-19 | Biovitrum Ab | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes |
| EP1414442A1 (en) * | 2001-08-07 | 2004-05-06 | Smithkline Beecham Plc | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
| DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| ES2187300B1 (es) * | 2001-11-14 | 2004-06-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
| GB0204720D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Novel use |
| JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物 |
| CN1662521A (zh) | 2002-06-20 | 2005-08-31 | 比奥维特罗姆股份公司 | 可用于治疗肥胖、ii型糖尿病和cns障碍的新化合物 |
| EP1776106B1 (en) * | 2004-06-22 | 2013-08-07 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives for modulation of calcium channels |
| US7582767B2 (en) | 2005-06-17 | 2009-09-01 | Biovitrum Ab (Publ.) | Substituted sulphonamide compound and uses thereof |
-
2003
- 2003-12-19 SE SE0303480A patent/SE0303480D0/sv unknown
-
2004
- 2004-12-20 CN CNA2004800354886A patent/CN1886392A/zh active Pending
- 2004-12-20 ZA ZA200603617A patent/ZA200603617B/en unknown
- 2004-12-20 JP JP2006545299A patent/JP4739230B2/ja not_active Expired - Fee Related
- 2004-12-20 US US11/018,019 patent/US7820675B2/en not_active Expired - Fee Related
-
2010
- 2010-09-28 US US12/892,765 patent/US20110015185A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2007514745A (ja) | 2007-06-07 |
| SE0303480D0 (sv) | 2003-12-19 |
| US20060287291A1 (en) | 2006-12-21 |
| US20110015185A1 (en) | 2011-01-20 |
| CN1886392A (zh) | 2006-12-27 |
| JP4739230B2 (ja) | 2011-08-03 |
| US7820675B2 (en) | 2010-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200603617B (en) | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-HT6 receptor-related disorder | |
| AU771460B2 (en) | Thrombopoietin mimetics | |
| JP6211509B2 (ja) | 複素環化合物およびその用途 | |
| KR100621272B1 (ko) | 퀴놀린 및 퀴나졸린 유도체 | |
| RU2386620C2 (ru) | Производные пиридазин-3(2н)-она и их применение в качестве ингибиторов фдэ4 | |
| DK2643313T3 (en) | Quinazolincarboxamidazetidiner | |
| ZA200502873B (en) | Substituted piperazines (1,4) diaszepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists | |
| JP2005510473A5 (sv) | ||
| CN102838546A (zh) | 作为5-ht2a 血清素受体调节剂用于治疗与其相关病症的吡唑衍生物 | |
| JPH07502739A (ja) | ５−ｈｔレセプター拮抗物質としてのピペラジン誘導体 | |
| ZA200508948B (en) | Substituted pyrazoles | |
| MXPA03011638A (es) | Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6. | |
| KR20080080172A (ko) | 치환 술폰아미드 화합물, ｃｎｓ 장애, 비만 및 ⅱ 형당뇨병 치료용 약제로서의 이들의 사용 방법 | |
| ATE452880T1 (de) | 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren | |
| ZA200403207B (en) | Therapeutic quinolone compounds with 5-HT-antagonistic properties. | |
| US20020107254A1 (en) | Serotonergic agents | |
| MXPA04007502A (es) | Derivados de quinolina como antagonistas de neuropeptido y (npy). | |
| EP1694663A1 (en) | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder | |
| RU2004117850A (ru) | Производные сульфонамида, их получение и применение в качестве лекарственных средств | |
| WO2006028161A1 (ja) | セロトニン５－ｈｔ３受容体作動薬 | |
| ES2349922T3 (es) | Pirazoles 1,3,4-substituidos como antagonistas del receptor de la 5-ht para el tratamiento de psicosis y de trastornos neurológicos. | |
| JPH06507893A (ja) | 不安緩解薬および鎮痙薬活性を有するベンゾ−およびピリドピラン誘導体 | |
| JP2004507527A5 (sv) | ||
| MXPA04005426A (es) | Derivados de pirazol de anillos fuisionados. | |
| KR20080105092A (ko) | 피롤 유도체 또는 그의 염 |